Dhaka, Sept. 15 -- Globe Biotech Limited has secured a United States Patent for its indigenously developed COVID-19 vaccine Bangavax, first of its kind in Bangladesh's pharmaceutical industry.

Globe Biotech, a subsidiary of Globe Pharma Group of Companies, made the announcement at a press conference titled "First US Patent in Bangladesh: A New Milestone in the Pharmaceutical Industry" at its Tejgaon office in the capital on Sunday.While giving a presentation, Dr. Kakon Nag, a scientist at Globe Biotech, said Bangavax is the only single-dose mRNA vaccine developed in Bangladesh that secured the US patent on August 26.

He pointed out that founded in 2015 the Globe Biotech expanded into COVID-19 research in 2020, developing diagnostic kits...